U.S. Induced Pluripotent Stem Cells (iPSCs) Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

U.S. Induced Pluripotent Stem Cells (iPSCs) Market Size

• The U.S. induced pluripotent stem cells (iPSCs) market size was valued at USD 242.28 million in 2024 and is expected to reach USD 546.40 million by 2032, at a CAGR of 10.70% during the forecast period
• The market growth is largely fueled by increasing research and development activities in regenerative medicine, disease modeling, and drug discovery, along with favorable government and private funding initiatives across the biotechnology sector
• Furthermore, the expanding use of iPSCs in personalized medicine and cell-based therapies is establishing them as a key resource in next-generation healthcare. These converging factors are accelerating the adoption of iPSC technologies, thereby significantly boosting the industry’s growth

U.S. Induced Pluripotent Stem Cells (iPSCs) Market Analysis

• U.S. Induced pluripotent stem cells (iPSCs), capable of differentiating into various human cell types, are becoming increasingly valuable tools in the U.S. for regenerative medicine, drug discovery, and disease modeling, due to their patient-specific origin, ethical viability, and compatibility with personalized therapeutic approaches
• The rising adoption of iPSCs in the U.S. is primarily fueled by growing R&D initiatives, increasing clinical trials involving iPSC-derived cell therapies, and robust public and private sector investment in advanced cell-based technologies
• A growing number of collaborations between academic institutions and biotechnology firms is accelerating the development and commercialization of iPSC-based therapies across various therapeutic areas
• Furthermore, advancements in reprogramming technologies and bioengineering are expanding the clinical applicability of iPSCs, particularly in areas such as cardiac regeneration, neurodegenerative diseases, and personalized medicine
• The 3D segment dominated the U.S. iPSCs market with a market share of 68.7% in 2024, driven by their superior ability to replicate in vivo environments, enhancing predictive accuracy in disease modeling and drug screening

Report Scope and U.S. Induced Pluripotent Stem Cells (iPSCs) Market Segmentation

U.S. Induced Pluripotent Stem Cells (iPSCs) Market Trends

“Advancement of 3D Culture Models and Organ-on-Chip Technologies”

• A significant and evolving trend in the U.S. iPSCs market is the increasing use of 3D culture systems and organ-on-chip platforms to simulate more physiologically relevant human tissue environments. These advanced systems are enhancing the predictive accuracy of disease models and accelerating drug discovery pipelines
• For instance, companies such as AxoSim and Emulate are utilizing iPSC-derived cells within microfluidic organ-on-chip platforms to replicate human organ functions and predict drug responses more effectively than traditional 2D cultures
• The integration of iPSC-derived cardiomyocytes, neurons, and hepatocytes into 3D and chip-based systems enables real-time monitoring of disease progression, toxicology, and efficacy, providing a more robust model for human biology. This is especially valuable in preclinical trials, where predictive accuracy can significantly reduce time and cost
• Moreover, 3D iPSC models support complex cell-to-cell interactions and tissue architecture, which are critical in studying diseases such as Alzheimer’s, ALS, and heart failure. These models allow researchers to generate patient-specific mini-organs (organoids), offering insights into personalized treatment strategies
• This trend is reshaping how pharmaceutical and biotech companies approach drug testing and disease modeling, with demand for iPSC-integrated platforms expected to grow across major therapeutic areas
• As U.S.-based companies increasingly invest in 3D bioprinting, microengineering, and stem cell technology, the market is witnessing rapid technological convergence aimed at replicating in vivo conditions with high fidelity, pushing the boundaries of what iPSCs can achieve in biomedical research and personalized care

U.S. Induced Pluripotent Stem Cells (iPSCs) Market Dynamics

Driver

“Growing Demand for Personalized Medicine and Regenerative Therapies”

• The increasing focus on personalized medicine and the growing burden of chronic and degenerative diseases in the U.S. are major drivers of iPSC adoption, as they offer the ability to generate patient-specific cells for precise disease modeling and individualized therapeutic strategies
• For instance, in March 2024, FUJIFILM Cellular Dynamics, Inc. announced an expanded portfolio of iPSC-derived immune cell products designed for use in precision oncology and immunotherapy research, marking a significant step toward personalized cell-based treatments
• The ability to derive any cell type from a patient’s own somatic cells makes iPSCs a valuable tool in regenerative therapies for neurological, cardiovascular, and hematologic disorders
• Moreover, the use of iPSCs in preclinical drug screening enhances safety and efficacy evaluation, helping pharmaceutical companies reduce time-to-market and improve drug candidate success rates. This capability has increased iPSC utility in major U.S. pharmaceutical pipelines
• Supportive regulatory frameworks and funding from agencies such as the NIH further bolster the integration of iPSCs into clinical research, enabling faster translation from bench to bedside

Restraint/Challenge

“High Cost of Development and Regulatory Complexity”

• Despite their potential, the U.S. iPSCs market faces significant challenges related to the high cost of generating, validating, and scaling iPSC-derived products. This includes expenses associated with specialized infrastructure, quality control, and GMP-compliant manufacturing processes
• For instance, the development of iPSC-based therapies often requires years of validation, extensive clinical trials, and adherence to strict FDA regulations, increasing both the timeline and financial burden for companies
• In addition, regulatory pathways for iPSC-derived products are still evolving, and developers must navigate a complex landscape of standards related to safety, efficacy, and ethical considerations, which can delay commercialization
• Ensuring cell line consistency, avoiding genetic abnormalities during reprogramming, and minimizing risks of teratoma formation remain key technical hurdles. Companies must invest heavily in quality assurance and long-term safety studies to gain regulatory approval
• Addressing these challenges through innovation in cost-effective reprogramming techniques, scalable production models, and early collaboration with regulatory bodies will be crucial for unlocking the full potential of iPSCs in the U.S. healthcare system

U.S. Induced Pluripotent Stem Cells (iPSCs) Market Scope

The market is segmented on the basis of model type, material, cell source, dimensional type, application, end use, and distribution channel.

• By Model Type

On the basis of model type, the U.S. induced pluripotent stem cells (iPSCs) market is segmented into ECM-patterned PAA/PDMS substrates, microgroove PDMS substrates, strained membranes, 3D scaffolds, free-floating hydrogel constructs, and engineered heart tissues (EHTs). The 3D scaffolds segment dominated the market with the largest market revenue share of 28.5% in 2024, driven by its ability to replicate native tissue structure and function, which is crucial for regenerative cardiac therapies and disease modeling.

The engineered heart tissues (EHTs) segment is anticipated to witness the fastest growth rate of 22.4% from 2025 to 2032, fueled by its rising use in cardiac toxicity testing, precision medicine, and high-throughput screening by pharmaceutical companies. The physiologically relevant data provided by EHTs is gaining widespread traction in translational research.

• By Material

On the basis of material, the U.S. induced pluripotent stem cells (iPSCs) market is segmented into natural hydrogel-based cardiac models and synthetic fibrous cardiac models. The natural hydrogel-based cardiac models segment held the largest market revenue share of 35.4% in 2024, due to its biomimetic properties, high biocompatibility, and strong support for cardiomyocyte growth and function in vitro.

The synthetic fibrous cardiac models segment is projected to register the fastest growth rate of 20.1% from 2025 to 2032, driven by its tunable mechanical properties, cost-efficiency, and suitability for scalable cardiac model manufacturing across biotech R&D labs.

• By Cell Source

On the basis of cell source, the U.S. induced pluripotent stem cells (iPSCs) market is segmented into skin cells and blood cells. The skin cells segment dominated the market with a revenue share of 61.2% in 2024, owing to the established reprogramming protocols, easier biopsy collection, and wide use in generating patient-specific iPSCs for cardiac applications.

The blood cells segment is expected to grow at the fastest CAGR of 19.6% from 2025 to 2032, as their non-invasive collection and rising donor acceptance drive demand in clinical-grade iPSC derivation and cardiovascular gene editing research.

• By Dimensional Type

On the basis of dimensional type, the U.S. induced pluripotent stem cells (iPSCs) market is segmented into 2D and 3D. The 3D segment accounted for the largest market share of 68.7% in 2024, attributed to its enhanced simulation of human cardiac tissue environments, offering more reliable data for drug screening and disease modeling.

The 2D segment is expected to register a slower yet consistent CAGR of 12.8% from 2025 to 2032, driven by its low-cost setup and continued utility in foundational research and education.

• By Application

On the basis of application, the U.S. induced pluripotent stem cells (iPSCs) market is segmented into production of new cardiac tissue to replace tissue destroyed by infarction or other diseases, heart failure, ischemic heart disease, arrhythmia, cardiomyopathies, valvular heart disease, heart disease screening, and others. The heart failure segment led the market with the highest revenue contribution of 26.9% in 2024, driven by increasing prevalence and the urgent clinical need for functional tissue regeneration using iPSC-derived cardiomyocytes.

The ischemic heart disease segment is anticipated to experience the fastest growth rate of 21.9% from 2025 to 2032, supported by increasing R&D investments and clinical trials evaluating iPSC-based interventions for myocardial restoration.

• By End Use

On the basis of end use, the U.S. induced pluripotent stem cells (iPSCs) market is segmented into pharmaceutical & biotechnology companies, academic and government research institutes, contract development & manufacturing organizations (CDMOs), and others. The pharmaceutical & biotechnology companies segment dominated the market with a share of 42.8% in 2024, owing to increasing adoption of iPSC-derived cardiac models in drug discovery, cardiotoxicity screening, and cell therapy development.

The contract development & manufacturing organizations (CDMOs) segment is anticipated to witness the fastest growth of 23.2% from 2025 to 2032, as outsourcing of stem cell production and model development becomes increasingly popular to accelerate R&D timelines.

• By Distribution Channel

On the basis of distribution channel, the U.S. induced pluripotent stem cells (iPSCs) market is segmented into direct tender and retail sales. The direct tender segment accounted for the largest market revenue share of 66.3% in 2024, driven by institutional bulk purchases by research centers and pharma companies engaged in cardiac regeneration trials.

The retail sales segment is projected to grow at the fastest CAGR of 18.4% from 2025 to 2032, supported by increased online distribution of iPSC kits, reagents, and small-scale models for independent researchers and labs.

U.S. Induced Pluripotent Stem Cells (iPSCs) Market Share

The U.S. Induced Pluripotent Stem Cells (iPSCs) industry is primarily led by well-established companies, including:

• FUJIFILM Cellular Dynamics, Inc. (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• Lonza Group Ltd (Switzerland)
• Takara Bio Inc. (Japan)
• Viacyte, Inc. (U.S.)
• Evotec SE (Germany)
• Astellas Pharma Inc. (Japan)
• Pluricell Biotech (Brazil)
• Axol Bioscience Ltd. (U.K.)
• Ncardia AG (Germany)
• REPROCELL Inc. (Japan)
• Fate Therapeutics, Inc. (U.S.)
• Bit Bio Ltd. (U.K.)
• BlueRock Therapeutics LP (U.S.)
• Century Therapeutics, Inc. (U.S.)
• StemCell Technologies Inc. (Canada)
• Charles River Laboratories International, Inc. (U.S.)
• Novo Nordisk A/S (Denmark)
• Generate:Biomedicines, Inc. (U.S.)
• BrainXell, Inc. (U.S.)

What are the Recent Developments in U.S. Induced Pluripotent Stem Cells (iPSCs) Market?

• In May 2023, FUJIFILM Cellular Dynamics, Inc., a leading player in the iPSC space, launched a new iPSC-derived cardiac platform tailored for high-throughput screening applications. Designed to enhance the predictive accuracy of cardiotoxicity testing, the platform supports pharmaceutical companies in streamlining early-stage drug discovery. This launch reinforces FUJIFILM’s strategic commitment to expanding its iPSC portfolio and delivering physiologically relevant cell models for cardiac safety assessment and regenerative medicine
• In April 2023, Thermo Fisher Scientific Inc. expanded its cell therapy manufacturing facility in Princeton, New Jersey, with a dedicated suite for iPSC-based product development. The upgrade aims to scale up iPSC reprogramming, differentiation, and banking services to meet the growing demand from academic institutions and biotech firms. The expansion reflects Thermo Fisher’s focus on providing end-to-end iPSC solutions, facilitating advanced research and translational applications in cardiovascular disease
• In March 2023, Fate Therapeutics, Inc. announced promising preclinical results from its iPSC-derived cardiomyocyte therapy program for ischemic heart failure. The study demonstrated significant improvement in cardiac function and reduced scar tissue in rodent models. These findings highlight the therapeutic potential of iPSC-based regenerative therapies and bolster Fate’s pipeline targeting severe cardiac disorders with off-the-shelf, immune-evasive cell therapies
• In February 2023, Cedars-Sinai Medical Center partnered with the California Institute for Regenerative Medicine (CIRM) to establish a statewide iPSC biobank for cardiovascular research. This initiative aims to accelerate the development of personalized therapies by collecting patient-specific iPSCs and supporting disease modeling for genetic heart diseases. The collaboration underscores growing institutional efforts to drive precision medicine using iPSC-derived cell systems
• In January 2023, Charles River Laboratories International, Inc. launched a contract service for GMP-grade iPSC production targeting cardiac applications. The new offering supports biotechnology companies engaged in developing iPSC-derived cardiac tissues for clinical trials and therapeutic use. This move highlights Charles River’s focus on scaling iPSC technologies to support regenerative medicine innovations and enhance clinical translation across the cardiovascular space

SKU-70419